怀孕期间雌激素代谢途径和随后的乳腺癌风险:一项前性后续研究
R Troisi1, R T Falk2, H M Surcel3
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. troisir@mail.nih.gov.
Breast cancer research : BCR
|January 16, 2026
概括
怀孕期间母亲雌激素的升高与激素受体阴性 (HR-) 乳腺癌的风险增加有关. 这项研究发现更高的雌激素水平和特定的代谢物与随后的HR-乳腺癌发展有关.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 在瘤学瘤学.
- 代谢学 代谢学 代谢学
背景情况:
- 怀孕后的乳腺癌风险,特别是荷尔蒙受体阴性 (HR-) 瘤的风险较高.
- 在怀孕的乳房重塑阶段,高水平的母体循环雌激素与HR瘤风险有关.
- 怀孕期间雌激素代谢对随后的HR-乳腺癌风险的影响尚不清楚.
研究的目的:
- 研究怀孕期间母亲血清雌激素和代谢物水平之间的关联以及随后激素受体阴性 (HR-) 乳腺癌的风险.
- 为了确定妊娠期间雌激素代谢途径是否影响HR-乳腺癌风险.
主要方法:
- 基于人口的病例控制研究,使用芬兰孕产妇队列生物库和芬兰癌症注册表.
- 怀孕第一和第二个三个月的血清样本用LC-MS/MS分析雌激素和代谢物.
- 使用条件逻辑回归比较了侵袭性,ER-/PR-乳腺癌病例 (n=449) 和匹配的对照 (n=449).
主要成果:
- 总雌激素与ER-/PR-乳腺癌风险积极相关 (或翻倍:1.16;95% CI1.02-1.32).
- 特定的16-基化途径代谢物 (醇,16-烯醇,17-烯醇) 与HR-乳腺癌风险有积极关联.
- 没有发现与2:16基化途径代谢物的比率有明确的关联;因平价或年龄的相互作用并不显著.
结论:
- 怀孕期间的孕产妇雌激素代谢物与患上主要是绝经前ER-/PR-乳腺癌的风险有关.
- 没有特定的代谢途径占主导地位,这表明怀孕期间的总雌激素度与随后的HR-乳腺癌风险有关.
- 这些发现突出了怀孕激素特征对长期乳腺癌风险的潜在影响.
相关概念视频
Oogenesis
69.1K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
69.1K
Teratogenicity
4.0K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
407
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
407
Cancer Prevention
7.7K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
7.7K
Disorders of the Female Reproductive System
3.9K
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
3.9K
Mutagenicity and Carcinogenicity
1.9K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.9K


